Furthermore, high dose therapy is likely to counteract tumor adaptation to the drugs, e.g. to induce rapid killing of cancer cells and therefore decrease the probability of developing secondary BRCA1-restoring mutations. This evidence concerns the gene BRCA1 and neoplasm.